New Zealand markets open in 5 hours 11 minutes
  • NZX 50

    11,617.14
    +6.15 (+0.05%)
     
  • NZD/USD

    0.6377
    +0.0024 (+0.38%)
     
  • ALL ORDS

    7,369.40
    -53.80 (-0.72%)
     
  • OIL

    72.59
    +0.58 (+0.81%)
     
  • GOLD

    1,805.80
    +7.80 (+0.43%)
     

Could This Biosimilar Drug Candidate Be a Hit for Novartis?

Could This Biosimilar Drug Candidate Be a Hit for Novartis?

On Sept. 19, Novartis (NYSE: NVS) shared positive news with investors regarding the clinical trial results for its biosimilar drug candidate to Amgen's (NASDAQ: AMGN) osteoporosis medicine Prolia. With Prolia set to lose exclusivity in the U.S. in 2025, Novartis could be close to booking some revenue from its biosimilar drug. Let's go over the outcome of the clinical trial and the U.S. osteoporosis market to figure this out.